BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37382251)

  • 21. Assessing the Implementation Determinants of Pilot Malaria Vaccination Programs in Ghana, Kenya, and Malawi through a Complexity Lens: A Rapid Review Using a Consolidated Framework for Implementation Research.
    Adamu AA; Jalo RI; Ndwandwe D; Wiysonge CS
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the safety, impact and effectiveness of RTS,S/AS01
    Praet N; Asante KP; Bozonnat MC; Akité EJ; Ansah PO; Baril L; Boahen O; Mendoza YG; Haine V; Kariuki S; Lamy M; Maleta K; Mungwira R; Ndeketa L; Oduro A; Ogutu B; Olewe F; Oneko M; Orsini M; Roman F; Bahmanyar ER; Rosillon D; Schuerman L; Sing'oei V; Terlouw DJ; Wéry S; Otieno W; Pirçon JY
    Malar J; 2022 Apr; 21(1):132. PubMed ID: 35468801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Analysis of RTS, S/AS01 Malaria Vaccine Acceptance Rates and Influencing Factors: A Systematic Review.
    Ansar F; Azzam A; Rauf MS; Ajmal Z; Asad Ullah G; Rauf S; Akram R; Ghauri FK; Chudhary F; Iftikhar H; Iqbal A; Ahmad MB
    Cureus; 2024 May; 16(5):e60678. PubMed ID: 38899238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
    von Seidlein L
    Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness and public health impact of RTS,S/AS01
    Ndeketa L; Mategula D; Terlouw DJ; Bar-Zeev N; Sauboin CJ; Biernaux S
    Wellcome Open Res; 2020; 5():260. PubMed ID: 34632084
    [No Abstract]   [Full Text] [Related]  

  • 28. Challenges and lessons learned during the planning and early implementation of the RTS,S/AS01
    Grant J; Gyan T; Agbokey F; Webster J; Greenwood B; Asante KP
    Malar J; 2022 May; 21(1):147. PubMed ID: 35550113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with malaria vaccine uptake in Nsanje district, Malawi.
    Simbeye AJ; Kumwenda S; Cohee LM; Omondi D; Masibo PK; Wao H; Awandu SS
    Malar J; 2024 Apr; 23(1):105. PubMed ID: 38627704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
    Waitumbi JN; Anyona SB; Hunja CW; Kifude CM; Polhemus ME; Walsh DS; Ockenhouse CF; Heppner DG; Leach A; Lievens M; Ballou WR; Cohen JD; Sutherland CJ
    PLoS One; 2009 Nov; 4(11):e7849. PubMed ID: 19924281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with malaria vaccine uptake in Sunyani Municipality, Ghana.
    Tabiri D; Ouédraogo JCRP; Nortey PA
    Malar J; 2021 Jul; 20(1):325. PubMed ID: 34315489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post introduction evaluation of the malaria vaccine implementation programme in Ghana, 2021.
    Adjei MR; Amponsa-Achiano K; Okine R; Tweneboah PO; Sally ET; Dadzie JF; Osei-Sarpong F; Adjabeng MJ; Bawa JT; Bonsu G; Antwi-Agyei KO; Kaburi BB; Owusu-Antwi F; Juma E; Kasolo FC; Asiedu-Bekoe F; Kuma-Aboagye P
    BMC Public Health; 2023 Mar; 23(1):586. PubMed ID: 36991394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
    Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
    Elife; 2022 Jan; 11():. PubMed ID: 35060479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
    Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.
    von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S
    Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O
    Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of malaria vaccine uptake among children 6-24 months in the Kassena Nankana Municipality in the Upper East Region of Ghana.
    Yeboah D; Owusu-Marfo J; Agyeman YN
    Malar J; 2022 Nov; 21(1):339. PubMed ID: 36384655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
    RTS,S Clinical Trials Partnership
    PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.